68Ga-PSMA在伴骨转移的混合型肝细胞-胆管细胞癌中摄取
本文报告一例70岁男性,因前列腺特异性抗原轻度升高(8.1 μg/L)及核素骨扫描示成骨性转移、临床怀疑前列腺癌而转诊行68Ga-PSMA PET/CT进行原发分期。检查发现多发68Ga-PSMA高摄取骨病灶(低剂量CT上多伴溶骨性改变)及肝内高摄取灶,前列腺内未见异常高摄取灶。肝病灶经组织病理学证实为混合型肝细胞-胆管细胞癌。
要点
- 68Ga-PSMA PET/CT在前列腺癌分期中可发现骨及肝内高摄取灶,本例前列腺内未见异常摄取。
- 骨病灶多为68Ga-PSMA高摄取,低剂量CT上多伴溶骨性改变。
- 肝病灶经组织病理学证实为混合型肝细胞-胆管细胞癌,可表现为68Ga-PSMA高摄取。
核心结论
- 伴骨转移的混合型肝细胞-胆管细胞癌可表现为68Ga-PSMA高摄取,前列腺内未见异常高摄取灶。
研究设计与样本
- 个案报告:一例70岁男性,前列腺特异性抗原轻度升高(8.1 μg/L),核素骨扫描示成骨性转移,临床怀疑前列腺癌,转诊行68Ga-PSMA PET/CT进行原发分期。
主要发现
- 68Ga-PSMA PET/CT发现多发68Ga-PSMA高摄取骨病灶,低剂量CT上多伴溶骨性改变。
- 同时发现肝内68Ga-PSMA高摄取灶,前列腺内未见异常高摄取灶。
- 肝病灶组织病理学证实为混合型肝细胞-胆管细胞癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ga-PSMA PET is a rapidly evolving imaging modality for whole-body staging of prostate cancer. We report a case of a 70-year-old man with mildly elevated prostate-specific antigen (8.1 μg/L) and clinical suspicion of prostate cancer (osteoblastic metastases on radionuclide bone scan) who was referred for Ga-PSMA PET/CT for primary staging. Multiple Ga-PSMA-avid skeletal foci, mostly associated with lytic changes on low-dose CT, as well as hepatic foci of avid Ga-PSMA uptake, were identified. No abnormal focus of avid Ga-PSMA uptake was identified in the prostate. On histopathological examination, the liver lesion proved to be combined hepatocellular cholangiocarcinoma.
引用
- Alipour R, Gupta S, Trethewey S, et al. 68Ga-PSMA Uptake in Combined Hepatocellular Cholangiocarcinoma With Skeletal Metastases. Clin Nucl Med. 2017. PMID: 28806238. doi:10.1097/RLU.0000000000001771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。